A California-based biotech company is stealing the show during Wednesday’s premarket after it was announced that the FDA approved Udenyca Onbody, a device used to deliver Udenyca for cancer patients. According to the release, the company intends  to commercially launch the device in Q1 2024.

Shares of Coherus BioSciences Inc. (Nasdaq:CHRS) are already having quite the day before the opening bell, with traders currently bidding up shares at $2.96/share (+35.78% implied open for sellers) at the time of writing. It should be an exciting session for this small cap!

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Copyright © 2023 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.